About MCMi
MCMi is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response
FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure. More: About MCMi and our history
In this section
![News & events on typewriter](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/news-events-1600px.jpg?itok=9pBWd7e9)
MCMi news and events
Medical countermeasure-related news and events, updated almost daily
![Examples of MCMs include drugs, vaccines, and devices, such as diagnostic tests and personal protective equipment.](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/what-are-mcms-banner-final-web.jpg?itok=hs3_OIAi)
What are medical countermeasures?
MCMs are FDA-regulated products that may be used in a public health emergency
More about OCET
More about OCET
![Image representing collaborative partnerships](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/other-mcmi-partnerships-1600x900.png?itok=XIbCI-qN)
MCMi collaborations
FDA works with government agencies, non-government organizations, universities, and research centers to support public health preparedness and response efforts
![Various images representing activities of the Office of Counterterrorism and Emerging Threats, including law and policy, regulatory science, professional development, and medical countermeasure development and availability](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/ocet-banner-2020-1-9.jpg?itok=OukeCWfJ)
Office of Counterterrorism and Emerging Threats (OCET)
OCET coordinates the MCMi, and is part of the FDA Office of the Chief Scientist. Learn more in FDA Organization.
Publications and Reports
MCMi mission areas
![Gavel and stethoscope, representing medical countermeasure-related counterterrorism legislation](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/gavel_stethoscope_1600px.jpg?itok=8H_TTVOw)
MCM legal, regulatory & policy framework
Helping ensure that U.S. laws, regulations, and policies support preparedness and response for potential CBRN and emerging infectious disease threats.
![FDA scientist dividing plasma from individuals recently infected with dengue or West Nile viruses into smaller volume samples for distribution. These samples were part of a reference panel FDA created for qualified Zika test manufacturers, to determine if their tests can differentiate flaviviridae antibodies—that is, if the test can accurately show if a person was infected with Zika, dengue or West Nile, as antibodies for these viruses are very similar.](https://public4.pagefreezer.com:443/content/FDA/04-02-2024T13:07/https://www.fda.gov/files/styles/medium_3/public/aliquoting_1600px.jpg?itok=O-wYiqLd)
MCM regulatory science
Developing the tools, standards, and approaches to assess MCM safety, efficacy, quality and performance, and helping translate new technology into innovative, safe, and effective MCMs.
Paragraph Header
Contact Us
Assistant Commissioner for Counterterrorism Policy, and Director, OCET
For Updates on Twitter follow
@FDA_MCMi